RESUMEN
Objective To investigate the expression of secretagogin(SCGN) and chromogranin A(CgA) in pancreatic neuroen‐docrine tumors (PNETs) .Methods Totally 54 cases of PNETs hospitalized in our hospital from October 2007 to October 2013 were enrolled in our study .Immunohistochemical detection was used to determine secretagogin and CgA .Results Secretagogin and CgA were highly expressed in all PNETs specimens .Compared with CgA ,secretagogin were highly expressed in the non‐functional PNETs ,tumor volume>30 cm3 ,the enveloped ,vascular invasion and lymph node metastasis (P0 .05) .Conclusion The expression of secretagogin and CgA in tumor combined with PNETs pathologi‐cal characteristics can predict the severity of PNETs .
RESUMEN
Objective To explore the expression and clinical significance of secretagogne (SCGN) in neuroendocrinal tumors.Methods Immunohistochemistry was applied for detecting expression of SCGN,chromogranin A (CgA),synaptophysin (Syn) and neuronspecific enolase (NSE) in 45 cases of neuroendocrinal tumors.The difference between the expression of SCGN and the remaining indicators were compared.And different expression profiles of SCGN between groups categorized by sex,age and degree of differentiation were also compared.Results The positive expression rate of SCGN,CgA,Syn and NSE in neuroendocrinal tumors was 95.56％ (43/45),100.00％ (45/45),46.67％ (21/45) and 88.89％ (40/45) respectively,and the differences among them were statistically significant(P ＜ 0.01).Expression of SCGN was not correlated with the patient's sex,age and degree of differentiation (P＞ 0.05).Conclusions Most cases of neuroendocrinal tumors are positive for SCGN and SCGN is more sensitive than CgA.Syn is the most sensitive one for diagnosis of neuroendocrinal tumors.SCGN can be seen as a novel neuroendocrinal marker in the clinical diagnosis of neuroendocrinal tumors.